2',3'-dideoxyadenosine triphosphate and urea

2',3'-dideoxyadenosine triphosphate has been researched along with urea in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Baev, D; Cahn, P; Calarota, SA; De Forni, D; Katabira, E; Lori, F; Maserati, R; Rakhmanova, A; Stevens, MR; Testori, M	1

Trials

1 trial(s) available for 2',3'-dideoxyadenosine triphosphate and urea

Article	Year
VS411 reduced immune activation and HIV-1 RNA levels in 28 days: randomized proof-of-concept study for antiviral-hyperactivation limiting therapeutics. PloS one, 2012, Volume: 7, Issue:10 Topics: Adult; Analysis of Variance; Anti-HIV Agents; Biomarkers; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Delayed-Action Preparations; Deoxyadenine Nucleotides; Didanosine; Dideoxynucleotides; Double-Blind Method; Drug Administration Schedule; Drug Combinations; Female; HIV Infections; HIV-1; Humans; Immunomodulation; Male; Placebos; RNA, Viral; Urea; Viral Load	2012

Article

Year

VS411 reduced immune activation and HIV-1 RNA levels in 28 days: randomized proof-of-concept study for antiviral-hyperactivation limiting therapeutics.

PloS one, 2012, Volume: 7, Issue:10

Topics: Adult; Analysis of Variance; Anti-HIV Agents; Biomarkers; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Delayed-Action Preparations; Deoxyadenine Nucleotides; Didanosine; Dideoxynucleotides; Double-Blind Method; Drug Administration Schedule; Drug Combinations; Female; HIV Infections; HIV-1; Humans; Immunomodulation; Male; Placebos; RNA, Viral; Urea; Viral Load

2012